We also report that treatment of T2DM stroke with CD133 + Exo not only improves neuro-cognitive outcome but also attenuates the progression of NAFLD/NASH, thereby holding promise as a novel therapeutic agent for the treatment of T2DM stroke, and potentially, directly for NAFLD/NASH. This evidence concerns the gene PROM1 and Stroke.